Angiopoietin-2 predicts all-cause mortality in male but not female end-stage kidney disease patients on hemodialysis

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration

(2020) Arshad M. Khanani et al.   JAMA Ophthalmology

Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab

(2020) Majid Khan et al.   Cells

Endothelium structure and function in kidney health and disease

(2019) Noemie Jourde-Chiche et al.   Nature Reviews Nephrology

Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development

(2019) Jessica Gillen et al.   Current Oncology Reports

Simultaneous Inhibition of Angiopoietin-2 and VEGF-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial

(2019) Jayashree Sahni et al.   OPHTHALMOLOGY

Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease

(2019) Rehan M. Hussain et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Angiopoietin‐Tie signaling in kidney diseases: an updated review

(2019) Fang‐Fang He et al.   FEBS LETTERS

Role of melatonin in controlling angiogenesis under physiological and pathological conditions

(2019) Qiang Ma et al.   ANGIOGENESIS

Angiopoietin-2 promotes pathological angiogenesis and is a novel therapeutic target in murine non-alcoholic fatty liver disease

(2018) Sander Lefere et al.   HEPATOLOGY

Angiopoietin-2 exacerbates cardiac hypoxia and inflammation after myocardial infarction

(2018) Seung-Jun Lee et al.   JOURNAL OF CLINICAL INVESTIGATION

The Angiopoietin-Tie2 Signaling Axis in Systemic Inflammation

(2017) Samir M. Parikh   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2

(2016) Bradley J. Monk et al.   GYNECOLOGIC ONCOLOGY

Angiopoietin-2, Angiopoietin-1 and subclinical cardiovascular disease in Chronic Kidney Disease

(2016) Yi-Chun Tsai et al.   Scientific Reports

Angiopoietin-2 as a Prognostic Biomarker of Major Adverse Cardiovascular Events and All-Cause Mortality in Chronic Kidney Disease

(2015) Yi-Chun Tsai et al.   PLoS One

Effects of an anabolic steroid (Durateston) on testicular angiogenesis in peripubertal stallions

(2015) A. Teubner et al.   THERIOGENOLOGY

Endothelial destabilization by angiopoietin-2 via integrin β1 activation

(2015) Laura Hakanpaa et al.   Nature Communications

A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery

(2014) I. Vergote et al.   EUROPEAN JOURNAL OF CANCER

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

(2014) Bradley J Monk et al.   LANCET ONCOLOGY

Circulating angiopoietin-2, its soluble receptor Tie-2, and mortality in the general population

(2013) Roberto Lorbeer et al.   EUROPEAN JOURNAL OF HEART FAILURE

Divergent regulation of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor by hypoxia and female sex steroids in human endometrial stromal cells

(2013) Tomoko Tsuzuki et al.   European Journal of Obstetrics & Gynecology and Reproductive Biology

Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells

(2011) Roberta Mazzieri et al.   CANCER CELL

Angiopoietin-2 levels predict mortality in CKD patients

(2011) Sascha David et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Imbalances in serum angiopoietin concentrations are early predictors of septic shock development in patients with post chemotherapy febrile neutropenia

(2010) Brunna E Alves et al.   BMC INFECTIOUS DISEASES

Clinical and Genetic Correlates of Circulating Angiopoietin-2 and Soluble Tie-2 in the Community

(2010) Wolfgang Lieb et al.   Circulation-Cardiovascular Genetics

Circulating angiopoietin-2 levels increase with progress of chronic kidney disease

(2010) S. David et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Angiopoietin 2 and Cardiovascular Disease in Dialysis and Kidney Transplantation

(2009) Sascha David et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function

(2009) Wolfgang Lieb et al.   EUROPEAN HEART JOURNAL

Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors

(2009) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin

(2009) Sascha David et al.   JOURNAL OF HYPERTENSION

Angiopoietin-2 levels in glucose intolerance, hypertension, and metabolic syndrome in Asian Indians (Chennai Urban Rural Epidemiology Study–74)

(2009) Sathish Anuradha et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus

(2008) P Kumpers et al.   ANNALS OF THE RHEUMATIC DISEASES

Balance between Angiopoietin-1 and Angiopoietin-2 Is in Favor of Angiopoietin-2 in Atherosclerotic Plaques with High Microvessel Density

(2008) Simone Post et al.   JOURNAL OF VASCULAR RESEARCH